1
Participants
Start Date
February 29, 2008
Primary Completion Date
October 31, 2009
Study Completion Date
October 31, 2009
IPI-504
Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
Columbia University, New York
Univ. of Pittsburgh Cancer Institute, Pittsburgh
Winship Cancer Institute of Emory University, Atlanta
University of Miami - Sylvester Comprehensive Cancer Center, Miami
Vanderbilt Ingram Cancer Center, Nashville
Gabrail Cancer Center, Canton
Indiana Univ. Melvin and Bren Simon Cancer Center, Indianapolis
Mayo Comprehensive Cancer Center, Rochester
Washington School of Medicine, St Louis
University of Kansas Cancer Center, Kansas City
Univ. of TX, MD Anderson Cancer Center, Houston
University of Colorado Health Sciences Center, Aurora
Arizona Cancer Center, Tuscon
The Angeles Clinic and Research Institute, Los Angeles
Sharp Memorial Hospital, San Diego
Dana-Farber Cancer Institute, Boston
Dartmouth-Hitchcock Medical Center, Lebanon
Lead Sponsor
Infinity Pharmaceuticals, Inc.
INDUSTRY